MedWatch

Genmab CEO on possible settlement in dispute with Janssen: "I have no comment"

Genmab CEO Jan van de Winkel is not keen on commenting on the possibility of a settlement in the dispute between Genmab and partner Janssen concerning the distribution of earnings from the cancer drug Darzalex, according to Danish newspaper Børsen.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

Danish pharmaceutical company Genmab intends to defend the stances of the firm in its current dispute with its former partner Janssen Pharmaceuticals on the distribution of the earnings from the cancer drug Darzalex, according to Danish newspaper Børsen.

Genmab CEO Jan van de Winkel tells the newspaper that the arbitration case is actively ongoing but that the timing of the case is uncertain. On the matter of whether the dispute might end with a settlement, the CEO tells Børsen:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs